BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

BioLineRx Trading Down 1.7 %

Shares of BLRX stock opened at $0.46 on Tuesday. The company has a market cap of $36.93 million, a price-to-earnings ratio of -0.61 and a beta of 1.46. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The firm has a fifty day moving average price of $0.62 and a 200-day moving average price of $0.66. BioLineRx has a 1 year low of $0.43 and a 1 year high of $1.93.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $5.39 million during the quarter, compared to the consensus estimate of $3.93 million. As a group, equities analysts predict that BioLineRx will post -0.25 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BioLineRx stock. CVI Holdings LLC purchased a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 815,683 shares of the biotechnology company’s stock, valued at approximately $462,000. CVI Holdings LLC owned approximately 1.02% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is currently owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.